Greg Bial

Greg Bial is an accomplished professional with extensive experience in business development and scientific research. Currently serving as the Associate Business Development Manager for Nucleic Acid Therapeutics at Axolabs GmbH since January 2023, Bial focuses on transitioning oligo therapeutic programs into clinical trial phases. Prior to this, Bial spent over a decade at Yecuris Corporation, where roles included Client Services Group Manager and Manufacturing Scientist, emphasizing client relations, technical support, and process development for gene therapy models. Bial's earlier experience includes positions as a Production Scientist at Surface Tools and various internships at Oregon Health and Science University and Life Technologies. Bial holds dual Bachelor of Science degrees in Genetics & Cell Biology and Economics from Washington State University.